Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biolab australia pty ltd - chlorine present as trichloroisocyanuric acid; sodium tetraborate pentahydrate - tablet (inc. pellet, bolus, suppository, capsule) - chlorine present as trichloroisocyanuric acid mineral-chlorine-acid active 651.0 g/kg; sodium tetraborate pentahydrate mineral-boron other 68.0 g/kg - pool chlorine - swimming pool - outdoor - algae | bacteria

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biolab australia pty ltd - chlorine present as sodium dichloroisocyanurate; sodium tetraborate pentahydrate - granular formulation - chlorine present as sodium dichloroisocyanurate mineral-chlorine active 372.0 g/kg; sodium tetraborate pentahydrate mineral-boron other 100.0 g/kg - pool chemical - swimming pool - algae | bacteria | organic contaminant or waste

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - propiconazole; liquid hydrocarbon - emulsifiable concentrate - propiconazole triazole active 250.0 g/l; liquid hydrocarbon solvent other 630.0 g/l - fungicide - apricot | banana | barley | boronia | oats | peanut | peppermint - oil production only | perennial ryegrass crop | pineapple | p - barley leaf scald | base or butt rot - t. paradoxa | black sigatoka | blind seed disease | blossom blight - monilinia fructicola | blossom blight - monilinia laxa | cordana leaf spot - cordana johnstonii | cordana leaf spot - cordana musae | crown rust (puccinia coronata) on oats | early leaf spot on peanut | late leaf spot on peanut | leaf rust | leaf smut on poppy | leaf speckle on banana | leaf spot or yellow sigatoka on banana | net form of net blotch | pineapple disease | powdery mildew - bulmeria graminis | prune rust | rust on boronia | rust on mint | rust on peanut | septoria leaf blotch - suppession | septoria nodorum blotch on wheat | septoria tritici blotch | spot form net blotch - pyrenophora teres | stem rust | yellow leaf spot on wheat | yellow or stripe rust | barley scald | brown rot | butt rot | ceratocystis paradoxa | peanut rust | puccinia recondita f.sp. triti | puccinia striiformis | puccinia triticina | septoria tritici | sigatoka | wheat leaf rust | yellow rust | yellow sigatoka | yello

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biolab australia pty. ltd. - chlorine present as sodium dichloroisocyanurate; copper present as copper citrate; sodium persulphate; sodium tetraborate pentahydrate - granular formulation - chlorine present as sodium dichloroisocyanurate mineral-chlorine active 405.0 g/kg; copper present as copper citrate mineral-copper active 2.6 g/kg; sodium persulphate ungrouped other 200.0 g/kg; sodium tetraborate pentahydrate mineral-boron other 40.0 g/kg - pool chemical - swimming pool - algae | bacteria

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4 farmers australia pty ltd - propiconazole; hydrocarbon liquid - emulsifiable concentrate - propiconazole triazole active 250.0 g/l; hydrocarbon liquid solvent other 600.0 g/l - fungicide - apricot | banana | banana - interplanted with avocados | barley | boronia | peanut | peppermint - oil production only | perennia - base or butt rot - t. paradoxa | black sigatoka | blind seed disease | blossom blight - monilinia laxa | brown rot (blossom phase)- m. fructicola | brown rot (fruit phase) - m. fructicola | cordana leaf spot - cordana johnstonii | early leaf spot on peanut | late leaf spot on peanut | leaf rust | leaf smut on poppy | leaf speckle on banana | leaf spot or yellow sigatoka on banana | pineapple disease | powdery mildew on barley | powdery mildew on wheat | prune rust | rust on boronia | rust on mint | rust on peanut | septoria nodorum blotch on wheat | spot form net blotch - pyrenophora teres | stem rust | stripe rust | yellow leaf spot on wheat | brown rot | butt rot | ceratocystis paradoxa | peanut rust | puccinia recondita f.sp. triti | puccinia triticina | sigatoka | wheat leaf rust | yellow sigatoka | yellow spot

Israel - inglês - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - inhalation suspension for nebulisation - fluticasone propionate 0.5 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.children and adolescents from 4 to 16 years of age:treatment of acute exacerbations of asthma.

Israel - inglês - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - inhalation suspension for nebulisation - fluticasone propionate 2 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - glucosamine hydrochloride, quantity: 750 mg; borax, quantity: 13.3 mg (equivalent: boron, qty 1.5 mg); bovine sodium chondroitin sulfate, quantity: 225 mg (equivalent: chondroitin sulfate, qty 205 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; crospovidone; magnesium stearate; microcrystalline cellulose; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000; lecithin - maintain/support general health and wellbeing ; maintain/support bone health ; help maintain/support bone mineralisation ; helps maintain/supports healthy joint cartilage growth/development/production ; helps maintain/support joint cartilage health ; maintain/support joint health

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 720 elisa unit - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium; polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote aboriginal and torres strait islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. homosexual men : increased incidence of hepatitis a infection among homosexual males suggests that the disease may be sexually transmitted in this group. contacts of infected persons : since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. the use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. specific population groups known to have a higher incidence of hepatitis a: eg. australian aboriginals, recognised community-wide hav epidemics. individuals with chronic liver disease and recipients of liver transplants, as hepatitis a infections is likely to be more severe in these groups. many injecting drug users will have pre-existing liver disease from hepatitis b or hepatitis c infection. recipients of blood products, such as factor viii eg. haemophiliacs. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis d virus, hepatitis e or other pathogens known to infect the liver.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 1440 elisa unit - injection, suspension - excipient ingredients: polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; aluminium hydroxide hydrate; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote aboriginal and torres strait islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. homosexual men : increased incidence of hepatitis a infection among homosexual males suggests that the disease may be sexually transmitted in this group. contacts of infected persons : since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. the use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. specific population groups known to have a higher incidence of hepatitis a: eg. australian aboriginals, recognised community-wide hav epidemics. individuals with chronic liver disease and recipients of liver transplants, as hepatitis a infections is likely to be more severe in these groups. many injecting drug users will have pre-existing liver disease from hepatitis b or hepatitis c infection. recipients of blood products, such as factor viii eg. haemophiliacs. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis d virus, hepatitis e or other pathogens known to infect the liver.